title: [Effectiveness of urokinase used in combination with batroxobin (DF-521) in rat model of focal cerebral ischemia-reperfusion].
abstract: OBJECTIVE
  This study was designed to use urokinase (UK) in combination with batroxobin in thrombolytic therapy so as to see whether batroxobin(DF-521) would be effective for neuroprotection.
  
  
  METHODS
  The model of right middle cerebral artery occlusion (MCAO) in male SD rats was established. 120 rats were randomized into 9 groups, namely control group, sham control group, and groups that were treated with batroxobin and urokinase together or separately. Each group comprised 15 rats. Intracranial bleeding, infarct volume ratio and neurological function were observed.
  
  
  RESULTS
  Intracranial bleeding was found in 5 rats of the UK 5000 U/kg group, in 4 rats of the UK 5000 U/kg (2 h) + DF-521 5 BU/kg (2 h) group, and in only 1 rat of the UK 5000 U/kg (2 h) + DF-521 5 BU/kg (1 h) group. Cerebral infarct volume ratio was obviously reduced in 5 BU/kg batroxobin group. No difference was observed in neurological deficit scores.
  
  
  CONCLUSIONS
  5000 U/kg urokinase increased the risk of intracranial hemorrhage in rat MCAO model. Batroxobin either used separately or in combination with urokinase would not increase the risk of intracranial hemorrhage in rat MCAO model.
authors.affiliation: Department of Neurology, West China Hospital, Sichuan University, Chengdu 610044, China.
authors.forename: Xiang-shu
authors.initials: XS
authors.lastname: Hu
authors.forename: Dong
authors.initials: D
authors.lastname: Zhou
authors.forename: Xiang-yu
authors.initials: XY
authors.lastname: Hu
authors.forename: Yin-zhu
authors.initials: YZ
authors.lastname: Zhang
authors.forename: Lin-yu
authors.initials: LY
authors.lastname: Tian
authors.forename: Juan
authors.initials: J
authors.lastname: Huang
mesh_terms: D000818:Animals; D012103:Batroxobin / Q000009:adverse effects* / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy*; D008297:Male; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D012103:Batroxobin; D014568:Urokinase-Type Plasminogen Activator